|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Vlad Hogenhuis, Merck

S

Vlad Hogenhuis

General Manager for Neuroscience, Dermatology, and Ophthalmology, Merck

RECRUITED BY: Merck CEO Roy Vagelos

EXECS NEED: The courage to do what's right

I got a call from Dr. Vagelos, with the opportunity to be part of his mission" is how Vlad Hogenhuis, MD, introduces his 14-year career at Merck. Hogenhuis was getting a Wharton MBA at the time, but he has pharma in his blood. Born in the Netherlands to a long line of physicians—his father developed a migraine drug—he practiced medicine for four years before deciding to jump to industry.

Vlad Hogenhuis

He's climbed the Merck ladder by crossing from managing to managed care to licensing to R&D strategy. "I had a broad view early on," he says. Under CEO Dick Clark's new model integrating clinical and commercial, he directs both the late-stage pipeline and global marketing for a $1.7 billion three-disease franchise. "I have end-to-end accountability," he says. "There's full alignment of what the sales force does and what we do in marketing and even in Phase III."

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.